<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>20 untreated <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> patients and 1 patient relapsing after radiotherapy (17 stage IIB-IV and 4 stage I-IIA) were given <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi> and <z:chebi fb="0" ids="8382">prednisone</z:chebi> on a 21-day cycle </plain></SENT>
<SENT sid="1" pm="."><plain>The response rate was 95% and 16 patients (76%) achieved complete remission </plain></SENT>
<SENT sid="2" pm="."><plain>4 patients have relapsed 2, 5, 22 and 50 months after treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Survival was 100% at a median follow-up of 35 months </plain></SENT>
<SENT sid="4" pm="."><plain>However, due to dyspnoea on exertion in 2 patients, <z:chebi fb="0" ids="3139">bleomycin</z:chebi> will be abandoned, and the occurrence of two <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> questions the role of <z:chebi fb="0" ids="4911">etoposide</z:chebi> as a leukaemogenic agent </plain></SENT>
</text></document>